Esophageal Atresia COVID-19 – EAT – Patient reported outcomes study

16 April 2020

The COVID-19 Coronavirus is already the subject of scientific and medical research and we can expect more studies to be commissioned.

Many of these studies will consider the epidemiological aspects of the virus and there will also be clinical studies into how COVID-19 has impacted different groups of patients (including those with pre-existing conditions or those born with a congenital malformation such as oesophageal atresia).

In this context, EAT board members believe that it is also vitally important to capture, by an on-line survey, the experiences of Esophageal Atresia patients themselves who have contracted COVID-19. The information and outcomes reported through this survey will have the potential to assist clinicians and researchers in better understanding COVID-19 and its impact on patients, so that in any future outbreaks of this – or a similar disease – there is the prospect of improved treatments and outcomes.

The survey has been developed and is managed by EAT and is endorsed by INoEA (International Network on Esophageal Atresia).





One comment on “Esophageal Atresia COVID-19 – EAT – Patient reported outcomes study

  1. Mads Holst Jensen -

    My son has is a EAT patient. It is my sincere hope that you could forward information on the findings of the ESOPHAGEAL ATRESIA COVID-19 – EAT – PATIENT REPORTED OUTCOMES STUDY


Leave a Reply

Your email address will not be published.